Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: DaiS who wrote (21361)	4/26/1999 10:31:00 AM
From: Mkilloran	Read Replies (1) \| Respond to of 23519

Dais...article in the NY Times today reviews Vivus patent on Female SD ..how large the market is..could be bigger that the male Viagra market..and how Vivus has recorded the first patent for treating Female SD. Leland Wilson also quoted to say how much safer this would be for Females to have a local applied gel than take Viagra pills.

To: DaiS who wrote (21361)	4/26/1999 5:17:00 PM
From: Edderd	Read Replies (1) \| Respond to of 23519

DaiS Besides the discomfort of the congestion caused by the alprostadil the biggest drawback to MUSE is the distance the applicator has to be put into the urethra. Over 1 ". Thats why I mentioned the gel as a technique whereby the material could be squirted into the Fossa Navicularis and then easily massaged back into the urethra to be absorbed. At one time a local pharmacy was producing a liquid alprostadil for patients to use by squirting it into the urethra and getting good results (not tested). A smaller diameter inserter would IMO be a setback because it would be too sharp and patients could hurt themselves during insertion. Shorter would be good however. All IMO Ed